Oklahoma legislation · 2026 Regular Session
Oklahoma SB1642: Controlled dangerous substances; authorizing divided quantities for certain acute pain opioid prescriptions. Effective date.
Status: Chaptered, May 7, 2026
What the bill says
An Act relating to controlled dangerous substances; amending 63 O.S. 2021, Section 2-309I, as amended by Section 1, Chapter 257, O.S.L. 2022 (63 O.S. Supp. 2025, Section 2-309I), which relates to prescription limits and rules for opioid drugs; authorizing divided quantities for certain acute pain prescriptions; updating statutory language; modifying statutory references; and providing an effective date. SUBJECT: Opioid prescription guidelines.
From the enrolled text, April 30, 2026:
An Act relating to controlled dangerous substances; amending 63 O.S. 2021, Section 2-309I, as amended by Section 1, Chapter 257, O.S.L. 2022 (63 O.S. Supp. 2025, Section 2-309I), which relates to prescription limits and rules for opioid drugs; authorizing divided quantities for certain acute pain prescriptions; updating statutory language; modifying statutory references; and providing an effective date. SUBJECT: Opioid prescription guidelines SECTION 1. AMENDATORY 63 O.S. 2021, Section 2-309I, as amended by Section 1, Chapter 257, O.S.L. 2022 (63 O.S. Supp. 2025, Section 2-309I), is amended to read as follows: Section 2-309I. A. A practitioner shall not issue an initial prescription for an opioid drug in a quantity exceeding a seven-day supply for treatment of acute pain. Any opioid prescription for acute pain shall be for the lowest effective dose of an immediaterelease drug. B. Prior to issuing an initial prescription for an opioid drug in a course of treatment for acute or chronic pain, a practitioner shall: 1. Take and document the results of a thorough medical history, including the experience of the patient with nonopioid medication and nonpharmacological pain-management approaches and substance abuse history; 2. Conduct, as appropriate, and document the results of a physical examination; 3. Develop a treatment plan with particular attention focused on determining the cause of pain of the patient; 4. Access relevant prescription …
Sponsors
- (R) · primary sponsor